The efficacy and safety of anti-EGFR target agents in patients with potentially resectable metastatic colorectal cancer: a meta-analysis of randomized controlled trials

Maintenance strategies after anti-EGFR-based induction in metastatic colorectal cancer: A systematic review and bayesian network meta-analysis

(2023) Luca Mastrantoni et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial

(2022) Marc Ychou et al.   BRITISH JOURNAL OF CANCER

Remote ischemic postconditioning has a detrimental effect and remote ischemic preconditioning seems to have no effect on small intestinal anastomotic strength

(2022) Mathilde Skov Nygaard et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Treatment of Metastatic Colorectal Cancer: ASCO Guideline

(2022) Van K. Morris et al.   JOURNAL OF CLINICAL ONCOLOGY

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial

(2020) John A Bridgewater et al.   LANCET ONCOLOGY

Chemotherapeutic Effectiveness of Combining Cetuximab for Metastatic Colorectal Cancer Treatment: A System Review and Meta-Analysis

(2020) Rong Li et al.   Frontiers in Oncology

Surgical resectability of multisite metastatic colorectal cancer: Pushing the limits while appropriately selecting patients

(2019) Lindsay A. Bliss et al.   JOURNAL OF SURGICAL ONCOLOGY

Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome

(2019) Federico Innocenti et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy

(2019) Davide Ciardiello et al.   CANCER TREATMENT REVIEWS

Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)

(2019) Jean Marc Phelip et al.   DIGESTIVE AND LIVER DISEASE

A systems mechanism for KRAS mutant allele–specific responses to targeted therapy

(2019) Thomas McFall et al.   Science Signaling

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

(2019) Dung T. Le et al.   JOURNAL OF CLINICAL ONCOLOGY

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)

(2019) Dominik P. Modest et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment and optimization of liver volume before major hepatic resection: Current guidelines and a narrative review

(2018) Adeel S. Khan et al.   International Journal of Surgery

Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial

(2018) Shukui Qin et al.   JOURNAL OF CLINICAL ONCOLOGY

First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)

(2017) Alfredo Carrato et al.   EUROPEAN JOURNAL OF CANCER

The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials

(2017) Julian Walter Holch et al.   EUROPEAN JOURNAL OF CANCER

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

(2016) E. Van Cutsem et al.   ANNALS OF ONCOLOGY

FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study

(2016) C.-H. Köhne et al.   EJSO

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

(2015) A Rowland et al.   BRITISH JOURNAL OF CANCER

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis

(2015) Filippo Pietrantonio et al.   EUROPEAN JOURNAL OF CANCER

A review of conventional and drug-eluting chemoembolization in the treatment of colorectal liver metastases: principles and proof

(2015) David M Liu et al.   Future Oncology

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer

(2015) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

(2014) J. Y. Douillard et al.   ANNALS OF ONCOLOGY

Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial

(2014) T. Gruenberger et al.   ANNALS OF ONCOLOGY

FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)

(2013) L. Fornaro et al.   ANNALS OF ONCOLOGY

Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients WithKRASWild-Type Unresectable Colorectal Liver-Limited Metastases

(2013) Le-Chi Ye et al.   JOURNAL OF CLINICAL ONCOLOGY

Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial

(2013) Bernard Nordlinger et al.   LANCET ONCOLOGY

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

(2013) Jean-Yves Douillard et al.   NEW ENGLAND JOURNAL OF MEDICINE

What is the optimal neo-adjuvant treatment for liver metastasis?

(2013) Sigurdis Haraldsdottir et al.   Therapeutic Advances in Medical Oncology

Evolution of Long-Term Outcome of Liver Resection for Colorectal Metastases: Analysis of Actual 5-Year Survival Rates over Two Decades

(2012) Luca Viganò et al.   ANNALS OF SURGICAL ONCOLOGY

Effect of specialist decision-making on treatment strategies for colorectal liver metastases

(2012) R. P. Jones et al.   BRITISH JOURNAL OF SURGERY

Effect of specialist decision-making on treatment strategies for colorectal liver metastases (Br J Surg 2012; 99: 1263-1269)

(2012) R. M. Charnley   BRITISH JOURNAL OF SURGERY

Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study

(2012) Kjell Magne Tveit et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

(2011) C. Bokemeyer et al.   ANNALS OF ONCOLOGY

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

(2011) Timothy S Maughan et al.   LANCET

Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial

(2011) E. Assenat et al.   ONCOLOGIST

Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial

(2010) C Garufi et al.   BRITISH JOURNAL OF CANCER

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

(2010) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

(2009) Gunnar Folprecht et al.   LANCET ONCOLOGY

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

(2008) Astrid Lièvre et al.   JOURNAL OF CLINICAL ONCOLOGY